Cantitate/Preț
Produs

Lung Cancer 2021, Part 1, An Issue of Thoracic Surgery Clinics: The Clinics: Surgery, cartea 31-3

Editat de Farid M. Shamji
en Limba Engleză Hardback – 5 aug 2021
In this issue of Thoracic Surgery Clinics, guest editor Farid Shamji brings considerable expertise to the topic of Lung Cancer.
Citește tot Restrânge

Din seria The Clinics: Surgery

Preț: 61677 lei

Preț vechi: 64924 lei
-5% Nou

Puncte Express: 925

Preț estimativ în valută:
11808 12273$ 9790£

Carte tipărită la comandă

Livrare economică 29 ianuarie-12 februarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780323793537
ISBN-10: 0323793533
Pagini: 240
Dimensiuni: 178 x 254 mm
Greutate: 0.54 kg
Editura: Elsevier
Seria The Clinics: Surgery


Cuprins

How to Design and Foster Thoracic Oncology Multidisciplinary Cancer Conferences
Guiding Principles in the Management of Synchronous and Metachronous Primary Non-Small Cell Lung Cancer
When Is It Safe to Operate for Lung Cancer? Selection of Fiscally Responsible Cardiopulmonary Function Tests for Limited Resection (Wedge Resection and Segmentectomy), Standard Lobectomy, Sleeve Lobectomy, and Pneumonectomy
Management of Air Leaks and Residual Spaces Following Lung Resection
Extended Pulmonary Resection by Sleeve Lobectomy and Carinal Pneumonectomy: Selection and Technique
Role of the Thoracic Radiologist in the Evaluation and Management of Solid and Subsolid Lung Nodules
Recognition and Management of Acute and Late Complications of Pneumonectomy: Clinical Cases and Treatment
Constants and Currents in the Education and Training of General Thoracic Surgeons
Assessment and Rehabilitation of the Compromised Patient Prior to Thoracotomy
Is Small Cell Lung Cancer a Surgical Disease at the Present Time?
Embolotherapy in Bronchial Hemorrhage
Ethics for Thoracic Surgeons in the Management of Lung Cancer
Oligometastatic Lung Cancer Defined by Biology, Science, and Secondary Growths
Implications of Adverse Biological Factors and Management of Solitary Fibrous Tumors of the Pleura
Can Biologic Aggressiveness and Metastatic Potential of Primary Lung Cancer Be Predicted from Clinical Staging Alone?